Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy

M Chaudhari; M Vogel; C Wright; J Smith; S G Haworth

doi:10.1136/adc.2004.062885

Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy

Arch Dis Child Fetal Neonatal Ed. 2005 Nov;90(6):F527-8. doi: 10.1136/adc.2004.062885.

Authors

M Chaudhari¹, M Vogel, C Wright, J Smith, S G Haworth

Affiliation

¹ Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK. milind.chaudhari@nuth.northy.nhs.uk

Abstract

We report a case of severe pulmonary hypertension in a neonate associated with impaired alveolarisation and plexiform pulmonary arteriopathy. Treatment with oral sildenafil in addition to inhaled nitric oxide (NO) resulted in recovery from the pulmonary hypertensive crisis. Long term sildenafil therapy was associated with complete resolution of the pulmonary hypertension.

Publication types

Case Reports

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
Female
Humans
Hypertension, Pulmonary / drug therapy*
Hypertension, Pulmonary / etiology
Infant, Newborn
Lung Diseases / complications
Phosphodiesterase Inhibitors / therapeutic use*
Piperazines / therapeutic use*
Pulmonary Alveoli / pathology
Pulmonary Artery / pathology
Purines
Sildenafil Citrate
Sulfones
Vasodilator Agents / therapeutic use*

Substances

Phosphodiesterase Inhibitors
Piperazines
Purines
Sulfones
Vasodilator Agents
Sildenafil Citrate
3',5'-Cyclic-GMP Phosphodiesterases